3,514 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Bought by HighTower Advisors LLC

HighTower Advisors LLC bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) during the 4th quarter, HoldingsChannel reports. The institutional investor bought 3,514 shares of the biotechnology company’s stock, valued at approximately $484,000.

Several other large investors also recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB acquired a new position in Ascendis Pharma A/S in the 3rd quarter valued at $30,000. Jones Financial Companies Lllp boosted its stake in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 197 shares during the period. Blue Trust Inc. grew its holdings in Ascendis Pharma A/S by 415.2% in the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 328 shares during the last quarter. GAMMA Investing LLC grew its holdings in Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 214 shares during the last quarter. Finally, Sanctuary Advisors LLC bought a new position in Ascendis Pharma A/S in the 4th quarter worth approximately $203,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ASND shares. UBS Group started coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price objective on the stock. Evercore ISI raised their price target on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 18th. JPMorgan Chase & Co. upped their price objective on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, March 18th. Cantor Fitzgerald lifted their target price on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 25th. Finally, The Goldman Sachs Group upped their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $204.64.

Ascendis Pharma A/S Trading Down 2.1 %

Shares of ASND opened at $154.68 on Monday. The stock has a market cap of $9.39 billion, a PE ratio of -21.79 and a beta of 0.62. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $169.37. The stock has a 50 day simple moving average of $144.16 and a 200-day simple moving average of $137.34.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. On average, sell-side analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.